Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection
| Autor: | Nicolas Legrand, Skye McGregor, Rowena Bull, Sahar Bajis, Braulio Mark Valencia, Amrita Ronnachit, Lloyd Einsiedel, Antoine Gessain, John Kaldor, Marianne Martinello |
|---|---|
| Přispěvatelé: | University of New South Wales [Sydney] (UNSW), Royal Prince Alfred Hospital [Sydney, Australia], Central Australian Health Service [Alice Springs], Epidémiologie et Physiopathologie des Virus Oncogènes / Oncogenic Virus Epidemiology and Pathophysiology (EPVO (UMR_3569 / U-Pasteur_3)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité) |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Adult
Microbiology (medical) clinical methods MESH: Paraparesis Tropical Spastic human T-cell leukemia virus sexually transmitted diseases viruses [SDV]Life Sciences [q-bio] Review immune system diseases oncogenic virus hemic and lymphatic diseases MESH: HTLV-I Infections diagnostics Humans Leukemia-Lymphoma Adult T-Cell MESH: Leukemia-Lymphoma Adult T-Cell clinical therapeutics Human T-lymphotropic virus 1 MESH: Human T-lymphotropic virus 1 MESH: Humans General Immunology and Microbiology pathogenesis public health Public Health Environmental and Occupational Health virus diseases MESH: Adult HTLV-I Infections Paraparesis Tropical Spastic virology Infectious Diseases epidemiology MESH: Public Health |
| Zdroj: | Clinical Microbiology Reviews Clinical Microbiology Reviews, 2022, 35 (2), pp.e0007821. ⟨10.1128/cmr.00078-21⟩ Clin Microbiol Rev |
| ISSN: | 0893-8512 |
| DOI: | 10.1128/cmr.00078-21⟩ |
| Popis: | International audience; Human T-lymphotropic virus type 1 (HTLV-1) is estimated to affect 5 to 10 million people globally and can cause severe and potentially fatal disease, including adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The burden of HTLV-1 infection appears to be geographically concentrated, with high prevalence in discrete regions and populations. While most high-income countries have introduced HTLV-1 screening of blood donations, few other public health measures have been implemented to prevent infection or its consequences. Recent advocacy from concerned researchers, clinicians, and community members has emphasized the potential for improved prevention and management of HTLV-1 infection. Despite all that has been learned in the 4 decades following the discovery of HTLV-1, gaps in knowledge across clinical and public health aspects persist, impeding optimal control and prevention, as well as the development of policies and guidelines. Awareness of HTLV-1 among health care providers, communities, and affected individuals remains limited, even in countries of endemicity. This review provides a comprehensive overview on HTLV-1 epidemiology and on clinical and public health and highlights key areas for further research and collaboration to advance the health of people with and at risk of HTLV-1 infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|